Therapeutic and cosmetic applications of mangiferin: an updated patent review (patents published after 2013)

ABSTRACT

Introduction: Mangiferin and its derivatives possess diverse biological activities and desirable drug like properties. In continuation with the authors’ previous publication, the present study reviews recently published patents in correlation with efforts of drug development using mangiferin.

Areas covered: Patents published after the year 2013 were analyzed for therapeutic and cosmetic applications of mangiferin, its salts, derivatives, and preparations. Patent information pertaining to improving solubility and bioavailability of mangiferin and related bioactives has also been presented. Methods of extraction of mangiferin and poly herbal preparations have not been included. Biological testing data has been put forth to understand the clinical trial status of products comprising mangiferin and/or its derivatives.

Expert opinion: Mangiferin has been highlighted as a multitarget bioactive with therapeutic potential. Research efforts in the recent years have contributed to development of new mangiferin derivatives as well as mangiferin formulations with enhanced solubility and bioavailability. Improvements in drug delivery systems for mangiferin might contribute to designing clinical trials to validate its therapeutic potential in humans. Majority of the recent patents have been filed by Chinese inventors claiming second medical use of mangiferin or its related compounds. However, a number of these patents remain in the prosecution stage.

KEYWORDS:

• Mangiferin
• bioavailability
• drug delivery
• clinical trial
• second medical use

Article highlights

• Patent literature on mangiferin and its derivatives published after 2013 has been reviewed as continuation of the authors’ earlier work

• Newly reported pharmacological activity of known mangiferin compounds and development and therapeutic application of new derivatives have been discussed

• Inventions pertaining to enhancing solubility and bioavailability of mangiferin have been reviewed

• Information retrieved from the Integrity database has been used to present the drug development status of mangiferin and related bioactives, indicating that there is no active drug pipeline

• Over 60% of the recently published patents denote China as the priority country and the majority of the applications involve second medical use claims and remain in the prosecution stage

This box summarizes key points contained in the article.

Acknowledgments

F Quadri was supported by Project Assistantship from the Council of Scientific and Industrial Research, Govt. of India, New Delhi.

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Reviewer disclosure

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.